VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone
ISNES, Belgium, Jan. 3, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO,Cameron Reynolds updating the company's shareholders. In the letter, Mr. Reynolds outlines several significant accomplishments to date and highligh...
VolitionRx Limited to Attend Conferences in December
ISNES, Belgium, Dec. 5, 2017 /PRNewswire/ -- VolitionRx Limited
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update
ISNES, Belgium, Nov. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter endedSeptember 30, 2017. Volition management will host a conference call tomorrow,November 10, at 8:30 a.m. U.S. Eastern Time to disc...
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update
Conference call to take place Friday, November 10, 2017 at 8:30 am Eastern time ISNES, Belgium, Nov. 2, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onFriday, November 10 at 8:30 a.m. Eastern time to discuss its financial and operat...
VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits
ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multin...
VolitionRx Announces its European Colorectal Cancer Strategy
ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe. As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample),...
VolitionRx to Attend Two Major Conferences in Asia
ISNES, Belgium, Sept. 15, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will attend Asia Pacific Digestive Week (APDW) and will host a symposium at the Taiwan Digestive Disease Week (TDDW). Volition's Vice President of Asia, Dr. Jasmine Kway, comm...
Volition Granted Four Additional Patents
ISNES, Belgium, Sept. 14, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been granted four additional patents relating to its proprietary Nu.QTM platform. The newly-issued patents further strengthen Volition's intellectual property portfoli...
VolitionRx Limited to Attend Multiple Conferences in September
ISNES, Belgium, Sept. 6, 2017 /PRNewswire/ -- VolitionRx Limited
Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers
ISNES, Belgium, Aug. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced a three-year agreement to work with the renowned expert ProfessorStefan Holdenrieder at the Institute of Laboratory Medicine of the German Heart Center at the Technical University ofMunich, G...
VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update
ISNES, Belgium, Aug. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter endedJune 30, 2017. Volition management will host a conference call to discuss these results and provide a further business up...
VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update
Conference call to take place Thursday, August 10, 2017 at 8:30 am Eastern time ISNES, Belgium, Aug. 3, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced it will host a conference call onThursday, August 10, 2017 at 8:30 am Eastern time to discuss its financial and ope...
VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute
AUSTIN, Texas, July 19, 2017 /PRNewswire/ -- VolitionRx Limited (Volition; NYSE MKT: VNRX), announced it will host a conference call tomorrow,July 20 at 8:30 AM U.S. Eastern Time to discuss its participation in a large multi-center clinical study with the Great Lakes New England Clinical Validati...
Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute
AUSTIN, Texas, July 18, 2017 /PRNewswire/ -- Volition America, Inc. (Volition America), a wholly-owned subsidiary of VolitionRx Limited (Volition; NYSE MKT: VNRX), has signed an agreement to participate in a large multi-center clinical study with the Great Lakes New England Clinical Validation Ce...
Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress
ISNES, Belgium, June 30, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it will be presenting at the EuropaColon Advocacy Masterclass and will be exhibiting at the European Society for Medical Oncology Congress on Gastrointestinal Cancer (ESMO GI). EuropaColon works...
VolitionRx Limited Corrects an Earlier Announcement
ISNES, Belgium, June 27, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today has issued corrections to certain statements made in the press release issued by the Company onMay 9, 2017 regarding the Company's Nu.Q™ Colorectal Cancer Screening Triage Test. Due to the Company's administra...
VolitionRx Limited to Present at Multiple Investor Conferences in June
NAMUR, Belgium, May 26, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it is scheduled to present at multiple investor conferences in June. Dr. Scott Powell, Executive Vice President of Volition, will provide an update on Volition's business, clinical, regulatory and ...
A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays
NAMUR, Belgium, May 18, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced the publication of a research paper entitled "Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer". The study was published in Clinical Epigenetics in collaboratio...
VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update
NAMUR, Belgium, May 11, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) ("Volition") today announced financial results for the quarter endedMarch 31, 2017 and provided a business update. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "I am delighted with the...
VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test
New data confirms prior test results that Volition's novel blood test can accurately detect colorectal cancer and reduce colonoscopies NAMUR, Belgium, May 9, 2017 /PRNewswire/ -- At the Digestive Disease Week 2017 (DDW) inChicago, VolitionRx Limited (NYSE MKT: VNRX) presented results that contin...
